Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDFIC 1
2017-002338-21Phase 3Completed
- Sponsor
- Albireo Pharma
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of odevixibat in progressive familial intrahepatic cholestasis type 1 (PFIC1) and progressive familial intrahepatic cholestasis type 2 (PFIC2) (3 arms), sponsored by Albireo Pharma. Primary endpoint: Responder rate based on fasting serum bile acids. Started Jan 2018; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis type 1 (PFIC1)progressive familial intrahepatic cholestasis type 2 (PFIC2)
Beyond the preview
Go deeper on 2017-002338-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002338-21.